|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 801 PENNSYLVANIA AVENUE NW |
Address2 | SUITE 725 |
City | WASHINGTON |
State | DC |
Zip Code | 20004 |
Country | USA |
3. Principal place of business (if different than line 2)
City | Bridgewater |
State | NJ |
Zip Code | 08807 |
Country | USA |
|
5. Senate ID# 56838-12
|
||||||||
|
6. House ID# 351860000
|
TYPE OF REPORT | 8. Year | 2011 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date | |
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Edward Greissing Jr., Vice President, U.S. Corporate Affairs |
Date | 07/19/2011 |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CPT
16. Specific lobbying issues
HR 1249 "America Invents Act" provisions related to first to file, inter parties review and supplemental re-examination; intellectual property provisions in the pending South Korea, Columbia and Panama Free Trade Agreements
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Sean |
Callinicos |
|
|
|
Timothy |
Clark |
|
|
|
Mary Anne |
Dunlap |
|
|
|
Eddie |
Evans |
|
|
|
Edward |
Greissing |
Jr. |
|
|
Patrick |
McLain |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
sanofi-aventis U.S. Inc. is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially
benefit sanofi-aventis U.S. Inc., so too Sanofi SA, as the parent corporation, will benefit..
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
Repeal and defunding efforts and general issues regarding implementation of Public Law 111-148 "Patient Protection and Affordable Care Act" including all provisions of HR605 and S312 "Patients' Freedom to Choose Act," the Medication Therapy Management Program, transitions of care, and the Independent Payment Advisory Board (IPAB); awareness and issues related to patient access to diabetes care; awareness & issues related to patient access to atrial fibrillation care, including all provisions in HRes295 "Promoting
increased awareness, diagnosis, and treatment of atrial fibrillation to address the high morbidity and mortality rates and to prevent avoidable hospitalizations associated with this disease", issues related to efforts to move pseudoephedrine products to prescription drug status; education and awareness of influenza pandemic and biodefense funding in FY2012 funding bills; intellectual propterty issues in the WHO global pandemic vaccine allocation plans; education and awareness and general issues related to the reauthorization of the Pandemic and All Hazards Preparation Act; education and awareness of the company's global Access to Medicines Program; education and awareness of dengue; issues related to the Section 317 Program for vaccines; general issues related to prescription drug safety; and all provisions of S1002 "Safe Doses Act".
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Sean |
Callinicos |
|
|
|
Timothy |
Clark |
|
|
|
Mary Anne |
Dunlap |
|
|
|
Edward |
Greissing |
Jr. |
|
|
Patrick |
McLain |
|
|
|
Amy |
Redl |
|
|
|
Ann |
Taylor |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
sanofi-aventis U.S. Inc. is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially
benefit sanofi-aventis U.S. Inc., so too Sanofi SA, as the parent corporation, will benefit..
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MED
16. Specific lobbying issues
General discussions regarding the reauthorization of the Prescription Drug User Fee Act (PDUFA); and education and awareness of vaccine production and infrastructure needs
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Sean |
Callinicos |
|
|
|
Timothy |
Clark |
|
|
|
Edward |
Greissing |
Jr. |
|
|
Patrick |
McLain |
|
|
|
Amy |
Redl |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
sanofi-aventis U.S. Inc. is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially
benefit sanofi-aventis U.S. Inc., so too Sanofi SA, as the parent corporation, will benefit..
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
General issues related to the Medicare Part D program
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Sean |
Callinicos |
|
|
|
Timothy |
Clark |
|
|
|
Mary Anne |
Dunlap |
|
|
|
Edward |
Greissing |
Jr. |
|
|
Patrick |
McLain |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
sanofi-aventis U.S. Inc. is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially
benefit sanofi-aventis U.S. Inc., so too Sanofi SA, as the parent corporation, will benefit..
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAX
16. Specific lobbying issues
Extension of the U.S. R&D tax credit and all such provisions in HR942 "The American Research and Competitiveness Act of 2011"
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Mary Anne |
Dunlap |
|
|
|
Edward |
Greissing |
Jr. |
|
|
Patrick |
McLain |
|
|
|
Ann |
Taylor |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
sanofi-aventis U.S. Inc. is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially
benefit sanofi-aventis U.S. Inc., so too Sanofi SA, as the parent corporation, will benefit..
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TOR
16. Specific lobbying issues
Punitive damages provisions in HR5 "Help Efficient, Accessible, Low-cost, Timely Healthcare (HEALTH) Act; and general issues related to efforts to reform the Vaccine Injury Compensation Program.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Sean |
Callinicos |
|
|
|
Edward |
Greissing |
Jr. |
|
|
Patrick |
McLain |
|
|
|
Ann |
Taylor |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
sanofi-aventis U.S. Inc. is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially
benefit sanofi-aventis U.S. Inc., so too Sanofi SA, as the parent corporation, will benefit..
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address | |
||||||
City | |
State | |
Zip Code | |
Country | |
21. Client new principal place of business (if different than line 20)
City | |
State | |
Zip Code | |
Country | |
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
5 |
|
||||||
2 |
|
6 |
|
||||||
3 |
|
7 |
|
||||||
4 |
|
8 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 3 | 5 |
2 | 4 | 6 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
Sanofi SA (formerly sanofi-aventis SA) |
|
|
0.00 | 100 % |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 sanofi-aventis SA | 5 | 9 |
2 | 6 | 10 |
3 | 7 | 11 |
4 | 8 | 12 |